Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Arthrosi Therapeutics, Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. All of these actions are located within 1 distinct art unit, which points to a specialized and consistent technical focus for these pending applications. The prosecution is distributed among distinct examiners, so each pending matter is being evaluated by a different person, even though they all fall under the same technical classification.
HERNANDEZ, JACKSON J is the busiest examiner for the portfolio, currently handling 1 pending action. With 3 pending office actions in total, the workload is split, requiring the company to navigate different examiner approaches while operating within the specific constraints of the art unit. This degree of examiner diversity within the identified art unit means that the company's success will depend on its ability to present consistent technical arguments to different individuals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HERNANDEZ, JACKSON J | 1 | 51.4% | +45.0% |
| GONZALEZ, LUISALBERTO | 1 | 59.4% | +47.2% |
| ENGLISH, CONNOR KENNEDY | 1 | 60.0% | +51.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18725070 | PREPARATION OF A COMPOUND FOR THE TREATMENT OF GOUT OR HYPERURICEMIA | HERNANDEZ, JACKSON J | — |
| 18714015 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | GONZALEZ, LUISALBERTO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18725070 | PREPARATION OF A COMPOUND FOR THE TREATMENT OF GOUT OR HYPERURICEMIA | HERNANDEZ, JACKSON J | — |
| 18714015 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | GONZALEZ, LUISALBERTO | — |
| 18685798 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ENGLISH, CONNOR KENNEDY | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18725070 | PREPARATION OF A COMPOUND FOR THE TREATMENT OF GOUT OR HYPERURICEMIA | HERNANDEZ, JACKSON J | — | §102§103§112 | Non-Final OA | — | Pending | Jun 27, 2024 |
| 18714015 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | GONZALEZ, LUISALBERTO | — | §102§112 | Non-Final OA | — | Pending | May 28, 2024 |
| 18685798 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ENGLISH, CONNOR KENNEDY | 1625 | §103 | Non-Final OA | — | Pending | Feb 22, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial